Over the last 7 days, the Biotech industry has risen 2.1%, driven by gains from Alnylam Pharmaceuticals of 56%. This means that the industry has gained 12% over the past year. Earnings are forecast to grow by 25% annually.
Has the U.S. Biotech Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Wed, 26 Jun 2024 | US$1.2t | US$164.4b | -US$27,944,334,256.96 | 27.7x | -41.8x | 7.1x |
Fri, 24 May 2024 | US$1.1t | US$164.6b | -US$26,730,942,218.01 | 23.8x | -42.8x | 7x |
Sun, 21 Apr 2024 | US$1.1t | US$164.2b | -US$23,334,003,533.71 | 20.4x | -45.9x | 6.5x |
Tue, 19 Mar 2024 | US$1.2t | US$167.4b | -US$21,842,633,160.51 | 13.6x | -52.9x | 6.9x |
Thu, 15 Feb 2024 | US$1.1t | US$169.0b | -US$20,830,501,541.08 | 18.2x | -54.5x | 6.7x |
Sat, 13 Jan 2024 | US$1.4t | US$204.8b | -US$22,497,556,941.00 | 18.8x | -63.9x | 7x |
Mon, 11 Dec 2023 | US$1.3t | US$204.6b | -US$22,091,414,218.00 | 18.7x | -58.3x | 6.3x |
Wed, 08 Nov 2023 | US$1.2t | US$203.9b | -US$22,098,875,636.00 | 17.7x | -56.1x | 6.1x |
Fri, 06 Oct 2023 | US$1.3t | US$207.4b | -US$13,070,685,311.00 | 17x | -95.7x | 6x |
Sun, 03 Sep 2023 | US$1.3t | US$207.6b | -US$12,424,624,459.00 | 18.4x | -104.2x | 6.2x |
Tue, 01 Aug 2023 | US$1.2t | US$186.1b | -US$14,987,339,751.00 | 14.8x | -76.8x | 6.2x |
Thu, 29 Jun 2023 | US$1.1t | US$186.2b | -US$16,022,072,383.00 | 13.5x | -69.8x | 6x |
Sat, 27 May 2023 | US$1.1t | US$185.9b | -US$16,043,116,316.00 | 11.2x | -70x | 6x |
Mon, 24 Apr 2023 | US$1.2t | US$198.4b | -US$3,220,153,400.00 | 13.9x | -369.7x | 6x |
Wed, 22 Mar 2023 | US$1.1t | US$199.3b | -US$3,596,312,205.00 | 12.6x | -314x | 5.7x |
Fri, 17 Feb 2023 | US$1.1t | US$202.6b | US$30.0m | 16.2x | 38090.5x | 5.6x |
Sun, 15 Jan 2023 | US$1.2t | US$203.7b | US$1.8b | 14.5x | 670.9x | 5.8x |
Tue, 13 Dec 2022 | US$1.2t | US$202.7b | US$1.4b | 14.7x | 821.2x | 5.7x |
Thu, 10 Nov 2022 | US$1.1t | US$201.1b | US$920.9m | 12.9x | 1171.6x | 5.4x |
Sat, 08 Oct 2022 | US$1.0t | US$206.1b | US$5.4b | 14.9x | 190.3x | 5x |
Mon, 05 Sep 2022 | US$1.0t | US$206.4b | US$6.2b | 14.6x | 168.1x | 5x |
Wed, 03 Aug 2022 | US$1.0t | US$211.8b | US$11.2b | 15.8x | 92.7x | 4.9x |
Fri, 01 Jul 2022 | US$1.0t | US$212.2b | US$11.1b | 15.4x | 93.2x | 4.9x |
Sun, 29 May 2022 | US$1.0t | US$212.7b | US$11.2b | 15.5x | 91.9x | 4.8x |
Tue, 26 Apr 2022 | US$1.2t | US$226.5b | US$14.7b | 17.8x | 82.9x | 5.4x |
Thu, 24 Mar 2022 | US$1.3t | US$221.9b | US$10.7b | 19.2x | 118.7x | 5.7x |
Sat, 19 Feb 2022 | US$1.2t | US$216.5b | US$5.7b | 21.8x | 213.5x | 5.6x |
Mon, 17 Jan 2022 | US$1.3t | US$212.1b | US$2.5b | 24.4x | 527.3x | 6.2x |
Wed, 15 Dec 2021 | US$1.4t | US$211.9b | US$3.1b | 25.2x | 448.8x | 6.6x |
Fri, 12 Nov 2021 | US$1.5t | US$212.0b | US$4.1b | 26.9x | 354.3x | 6.9x |
Sun, 10 Oct 2021 | US$1.5t | US$196.3b | -US$2,597,765,814.00 | 23.3x | -560.6x | 7.4x |
Tue, 07 Sep 2021 | US$1.6t | US$196.4b | -US$2,275,254,373.56 | 21.9x | -703.6x | 8.2x |
Thu, 05 Aug 2021 | US$1.6t | US$197.0b | -US$1,413,253,338.58 | 23.1x | -1128.4x | 8.1x |
-1810.8x
Which industries have driven the changes within the U.S. Healthcare industry?
US Market | -0.27% | |
Healthcare | 0.76% | |
Biotech | 1.97% | |
Biotech | 1.97% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
ALNY Alnylam Pharmaceuticals | US$240.15 | 56.1% +US$10.9b | 27.2% | PS15.2x | |
GILD Gilead Sciences | US$69.61 | 10.2% +US$8.0b | -8.4% | PE178.8x | |
AMGN Amgen | US$319.31 | 4.4% +US$7.1b | 43.4% | PE45.5x | |
SRPT Sarepta Therapeutics | US$158.06 | 34.5% +US$3.8b | 48.6% | PE884.2x | |
REGN Regeneron Pharmaceuticals | US$1.07k | 3.1% +US$3.5b | 49.6% | PE30x |